Susquehanna Fundamental Investments LLC Invests $572,000 in Nuvation Bio Inc. (NYSE:NUVB)

Susquehanna Fundamental Investments LLC purchased a new position in shares of Nuvation Bio Inc. (NYSE:NUVB - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 215,198 shares of the company's stock, valued at approximately $572,000. Susquehanna Fundamental Investments LLC owned 0.06% of Nuvation Bio as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD increased its holdings in shares of Nuvation Bio by 4.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 225,025 shares of the company's stock valued at $599,000 after purchasing an additional 9,758 shares during the last quarter. Hsbc Holdings PLC raised its holdings in Nuvation Bio by 22.0% in the 4th quarter. Hsbc Holdings PLC now owns 143,223 shares of the company's stock valued at $378,000 after acquiring an additional 25,870 shares during the period. MetLife Investment Management LLC raised its holdings in Nuvation Bio by 13.8% in the 4th quarter. MetLife Investment Management LLC now owns 103,647 shares of the company's stock valued at $276,000 after acquiring an additional 12,596 shares during the period. Forum Financial Management LP acquired a new stake in Nuvation Bio during the fourth quarter worth approximately $29,000. Finally, Legal & General Group Plc boosted its holdings in shares of Nuvation Bio by 38.8% during the fourth quarter. Legal & General Group Plc now owns 224,827 shares of the company's stock worth $598,000 after acquiring an additional 62,877 shares during the period. Institutional investors and hedge funds own 61.67% of the company's stock.

Wall Street Analyst Weigh In

NUVB has been the subject of several research reports. Wedbush reissued an "outperform" rating and set a $5.00 price target on shares of Nuvation Bio in a report on Thursday, March 27th. Royal Bank of Canada reissued an "outperform" rating and issued a $10.00 target price (up previously from $6.00) on shares of Nuvation Bio in a research report on Tuesday, January 7th. Jones Trading began coverage on shares of Nuvation Bio in a research note on Wednesday, March 12th. They issued a "buy" rating and a $10.00 price target on the stock. Citigroup initiated coverage on shares of Nuvation Bio in a report on Wednesday, April 23rd. They issued an "outperform" rating for the company. Finally, Citizens Jmp initiated coverage on shares of Nuvation Bio in a report on Wednesday, April 23rd. They set a "mkt outperform" rating and a $6.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Nuvation Bio has a consensus rating of "Buy" and a consensus price target of $7.83.

Nuvation Bio Stock Down 2.9 %

Shares of NUVB stock traded down $0.06 during trading hours on Wednesday, reaching $2.03. The company's stock had a trading volume of 3,807,077 shares, compared to its average volume of 2,161,013. Nuvation Bio Inc. has a fifty-two week low of $1.54 and a fifty-two week high of $3.97. The company has a market capitalization of $687.52 million, a price-to-earnings ratio of -0.94 and a beta of 1.42. The firm's 50 day simple moving average is $1.97 and its 200-day simple moving average is $2.36.

Nuvation Bio (NYSE:NUVB - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). Sell-side analysts predict that Nuvation Bio Inc. will post -0.36 earnings per share for the current year.

Insider Activity at Nuvation Bio

In other news, insider Dongfang Liu sold 20,000 shares of the company's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $2.50, for a total value of $50,000.00. Following the completion of the transaction, the insider now owns 12,000 shares of the company's stock, valued at $30,000. This represents a 62.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO David Hung bought 200,000 shares of the business's stock in a transaction that occurred on Friday, April 4th. The shares were acquired at an average price of $1.66 per share, for a total transaction of $332,000.00. Following the completion of the transaction, the chief executive officer now owns 58,481,054 shares in the company, valued at $97,078,549.64. This trade represents a 0.34 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 29.93% of the stock is owned by insiders.

Nuvation Bio Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.